Business
-
AstraZeneca has announced that it will sell the Airsupra albuterol / budesonide MDI directly to US patients through a web site called AstraZeneca Direct starting October 1, 2025. According to the company, patients with a… Read more . . .
-
ReCode Therapeutics said that the Cystic Fibrosis Foundation will provide an additional $3 million for development of RCT2100 inhaled mRNA therapy for CF and that the company has closed a funding of more than $29… Read more . . .
-
Tonix Pharmaceuticals has announced plans for a Phase 2 trial of its TNX-2900 intranasal magnesium-potentiated oxytocin in patients with Prader-Willi syndrome (PWS). According to Tonix, the FDA has already cleared the company’s IND for a… Read more . . .
-
Gossamer Bio, which is developing inhaled dry powder seralutinib, announced a deal with Samsara BioCapital giving the company an option to acquire Respira Therapeutics along with Respira’s RT234 vardenafil DPI. On signing, Gossamer will issue 2.5 million… Read more . . .
-
Blow Fill Seal specialist Ritedose, which offers CDMO services and produces its own inhalation solutions, has announced that it will spend $17 million to add 10,000 sq ft of laboratory space, tripling its current lab… Read more . . .
-
Acadia Pharmaceuticals has announced that the Phase 3 COMPASS PWS trial of ACP-101 carbetocin nasal spray in Prader-Willi syndrome patients with hyperphagia failed to meet any of its endpoints, including the primary endpoint of change… Read more . . .
-
Inhaled mRNA developer Ethris and CDMO Evonik have announced a new partnership for development and commercialization of a lipid nanoparticle (LNP) platform for delivery of nucleic acid. Ethris’s SNaP LNP technology will become available to… Read more . . .
-
Strides Pharma Science announced a new development agreement between Strides Pharma Global and OINDP specialist CDMO Kenox Pharmaceuticals for “multiple nasal spray products for the US market across diverse therapeutic indications.” The company did not… Read more . . .
-
According to SoftOx Solutions, the company intends to conduct a Phase 1 proof-of-concept dose escalation study of SoftOx inhalation solution (SIS) in cystic fibrosis patients as part of a refocus away from development of SIS… Read more . . .
-
According to MannKind Corporation, United Therapeutics has exercised an option granted under a 2018 licensing and collaboration agreement between the companies for development of an additional dry powder inhalation product based on MannKind’s Technosphere technology. The… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden